Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay

Xenobiotica

Volumn 41, Issue 9, 2011, Pages 826-835

  Wang, Huijuan ^a   Kim, Raymond A ^b   Sun, Dongxu ^c   Gao, Yiwen ^a   Wang, Hao ^a   Zhu, Juanli ^d   Chen, Chao ^a  

^a NORTHWEST UNIVERSITY   (China)

^b GenePrism Inc   (United States)

^c JIANGSU NORMAL UNIVERSITY   (China)

^d Shaanxi Lifegen Co Ltd   (China)

Author keywords

CYP2C19; enzyme kinetics; fluorescence; genotype dependent drugdrug interactions; high throughput; single nucleotide polymorphism

Indexed keywords

3 CYANO 7 ETHOXYCOUMARIN; 7 ETHOXYCOUMARIN; CELECOXIB; CYTOCHROME P450 2C19; FLUCONAZOLE; FLUOXETINE; KETOCONAZOLE; OMEPRAZOLE; SERTRALINE; TICLOPIDINE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; DRUG INHIBITION; ENZYME KINETICS; FLUORESCENCE; HIGH THROUGHPUT SCREENING; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; YEAST CELL;

ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MUTANT PROTEINS; NITRILES; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; SACCHAROMYCES CEREVISIAE;

EID: 79961184789     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.582893     Document Type: Article

References (49)

1. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA. (2002).Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12:703-711. (Pubitemid 36054937)
2. Crespi CL, Miller VP, Penman BW. (1997).Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190. (Pubitemid 27218241)
3. Crespi CL, Stresser DM. (2000).Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 44:325-331. (Pubitemid 32239484)
4. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994a).Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598. (Pubitemid 24334747)
5. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. (1994b).The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
6. Donato MT, Jiménez N, Castell JV, Gómez-Lechón MJ. (2004). Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32:699-706. (Pubitemid 38821870)
7. Drögemöller BI, Wright GE, Niehaus DJ, Koen L, Malan S, Da Silva DM, Hillermann-Rebello R, La Grange AM, Venter M, Warnich L. (2010).Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11:1095-1103.
8. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA. (1998).A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361. (Pubitemid 28109566)
9. Gao Y, Liu D, Wang H, Zhu J, Chen C. (2010).Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotypedependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica 40:467-475.
10. Guengerich FP. (1997).Role of cytochrome P450 enzymes in drug- drug interactions. Adv Pharmacol 43:7-35.
11. Hanioka N, Tsuneto Y, Saito Y, Maekawa K, Sawada J, Narimatsu S. (2008).Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Basic Clin Pharmacol Toxicol 102:388-393. (Pubitemid 351393113)
12. Hanioka N, Tsuneto Y, Saito Y, Sumada T, Maekawa K, Saito K, Sawada J, Narimatsu S. (2007).Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica 37:342-355. (Pubitemid 46572886)
13. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. (1989).Sitedirected mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59. (Pubitemid 19125653)
14. Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, Tracy TS. (2005).CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68:644-651. (Pubitemid 41206018)
15. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. (1999).A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635-640. (Pubitemid 29344556)
16. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA. (1998a).An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8:129-135. (Pubitemid 28227321)
17. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J. (1998b).Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490-1495. (Pubitemid 29135566)
18. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007).Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. (Pubitemid 350116943)
19. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. (1996). Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78. (Pubitemid 26300937)
20. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman- Sundberg M. (1994).Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459. (Pubitemid 24296678)
21. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. (2009).Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
22. Kita T, Tanigawara Y, Aoyama N, Hohda T, Saijoh Y, Komada F, Sakaeda T, Okumura K, Sakai T, Kasuga M. (2001).CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 18:615-621. (Pubitemid 32595789)
23. Krippendorff BF, Lienau P, Reichel A, Huisinga W. (2007).Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery. J Biomol Screen 12:92-99. (Pubitemid 46224923)
24. Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS. (2008). Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36:1242-1248. (Pubitemid 351929306)
25. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. (2006).CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975. (Pubitemid 44837757)
26. Lee SJ, Kim WY, Kim H, Shon JH, Lee SS, Shin JG. (2009).Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos 37:2262-2269.
27. Lewis DF. (2002).Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 32:305-323. (Pubitemid 34596865)
28. Liu D, Gao Y, Wang H, Zi J, Huang H, Ji J, Zhou R, Nan Y, Wang S, Zheng X, Zhu J, Cui Y, Chen C. (2010).Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential. Drug Metab Dispos 38:2259-2265.
29. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362.
30. Morita J, Kobayashi K, Wanibuchi A, Kimura M, Irie S, Ishizaki T, Chiba K. (2004).A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4́-hydroxylation. Drug Metab Pharmacokinet 19:236-238.
31. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006).The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
32. Oda A, Yamaotsu N, Hirono S. (2004).Studies of binding modes of (S)- mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking. Pharm Res 21:2270-2278. (Pubitemid 40568441)
33. Omura T, Sato R. (1964).The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
34. Rosemary J, Adithan C. (2007).The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2:93-109.
35. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. (2006).A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113. (Pubitemid 43069582)
36. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. (1999).Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 47:454-457. (Pubitemid 29161281)
37. Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. (2006). Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 61:309-314. (Pubitemid 43382630)
38. Wang H, An N, Wang H, Gao Y, Liu D, Bian T, Zhu J, Chen C. (2011). Evaluation of the Effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4́-hydroxylation and omeprazole 5́-hydroxylation. Drug Metab Dispos 39:830-837.
39. Wang JF, Wei DQ, Chen C, Li Y, Chou KC. (2008).Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept Lett 15:27-32. (Pubitemid 351206472)
40. Wang JF, Wei DQ, Li L, Zheng SY, Li YX, Chou KC. (2007).3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun 355:513-519. (Pubitemid 46282658)
41. Weaver R, Graham KS, Beattie IG, Riley RJ. (2003).Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/ multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31:955-966. (Pubitemid 36759067)
42. Wedlund PJ. (2000).The CYP2C19 enzyme polymorphism. Pharmacology 61:174-183.
43. Wienkers LC, Heath TG. (2005).Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. (Pubitemid 41553963)
44. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH. (1997).Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281:604-609. (Pubitemid 27203121)
45. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. (2004a).Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 44:1223-1229. (Pubitemid 39391480)
46. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. (2004b).Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487-494. (Pubitemid 38519654)
47. Yoichi N, Yuriko T, Shigeyuki T, Akira K. (2004).Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of single method for detecting quasiirreversible and irreversible inhibitors. Drug Metab Pharmacokinet 19:55-61.
48. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, Shin SG. (2001).Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69:266-273. (Pubitemid 32382510)
49. Zanger UM, Turpeinen M, Klein K, Schwab M. (2008).Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.